John Mark O'Mahony - 30 Jun 2025 Form 4 Insider Report for LEAP THERAPEUTICS, INC. (LPTX)

Role: Chief Manufacturing Officer
Signature: /s/ Douglas E. Onsi, as attorney-in-fact for John Mark O'Mahony
Issuer symbol: LPTX
Transactions as of: 30 Jun 2025
Net transactions value: $0
Form type: 4
Filing time: 01 Jul 2025, 16:30:15 UTC
Previous filing: 01 Apr 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
O'Mahony John Mark	Chief Manufacturing Officer	C/O LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE	/s/ Douglas E. Onsi, as attorney-in-fact for John Mark O'Mahony	01 Jul 2025	0001808556

John Mark O'Mahony is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Remarks:

The reporting person is no longer serving as the Chief Manufacturing Officer of Leap Therapeutics, Inc., effective June 30, 2025. As a result, the reporting person is no longer subject to Section 16 in connection with his transactions in the equity securities of Leap Therapeutics, Inc. and therefore will no longer report any such transactions on Form 4 or Form 5.